A systematic review found a limited evidence base for pharmacological anxiety treatment near the end of life.
What the source reports
Five studies met inclusion criteria: two assessed benzodiazepine-opioid combinations and three assessed psilocybin. The authors described anxiety improvement and favorable tolerability in those studies, while emphasizing small samples and narrow clinical contexts.
Limits and uncertainty
The two benzodiazepine-opioid reports do not establish the effect of either drug alone. Different treatment categories and study populations should not be treated as an interchangeable pooled intervention. Few serious events in small selected samples cannot exclude uncommon or context-dependent harm.
Implications for forensic review
For an end-of-life review, separate anxiety relief, sedation depth, dyspnea, and treatment goals. This synthesis supports discussing uncertainty and symptom-specific benefit. It does not prove that combining a benzodiazepine with an opioid is uniformly safe or necessary in every palliative-care patient.
Source and related reading
Source reviewed: Pharmacological Management of Anxiety in End of Life Care A Systematic Review of Benzodiazepines Opi (PMC12780303). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: CBT-Assisted Benzodiazepine Discontinuation Evidence Came From Only Three Anxiety Trials; Opioid Co-Use Changed the Mortality Comparison for Benzodiazepine Hypnotics in Older Adults.
Leave a Reply